Arrowhead Pharmaceuticals Inc (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arrowhead Pharmaceuticals Inc , where a total of 3,324 contracts have traded so far, representing approximately 332,400 underlying shares. That amounts to about 61.7% of ARWR's average daily trading volume over the past month of 538,710 shares.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, August 9, 2016, at 4:30 p.

Investors eyeing a purchase of Arrowhead Pharmaceuticals Inc shares, but cautious about paying the going market price of $5.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 45 cents.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV)...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic...

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-a for the treatment of renal cell carcinoma (RCC), at the American Association for...

Arrowhead Pharma (ARWR) stock continued to climb on Thursday after the release of ‘promising’ data about its lead product candidate for the treatment of the hepatitis B infection yesterday.

Arrowhead Pharma (ARWR) stock are rising following the release of encouraging data about the company's lead product candidate for the treatment of the hepatitis B virus infection.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver...

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc.

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented additional preclinical data suggesting that ARC-F12, an RNAi therapeutic that inhibits the...

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a weak on high relative volume candidate

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2016 first quarter ended December 31, 2015.

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate